Drug Trial Radar · NCT06507436
The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
127
Actual
Start
Jul 31, 2024
Primary completion
Aug 14, 2026
Study completion Aug 14, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study includes Part A and Part B. Part A is a dose-finding study for subjects with chronic liver disease-related thrombocytopenia scheduled for elective surgery. Part B is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study designed to evaluate the efficacy and safety of Herombopag compared to placebo in patients with chronic liver disease-related thrombocytopenia undergoing elective invasive surgery.
Conditions
- Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery
Interventions
Herombopag tabletsDrug
Herombopag tablets; dose 1 or dose 2, for 5 days
Herombopag placebo tabletsDrug
Herombopag placebo tablets; dose 1 or dose 2, for 5 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: CL/FTime frame: 0 minute to 5 days
- Part A: Vc/FTime frame: 0 minute to 5 days
- Part A: kaTime frame: 0 minute to 5 days
- Part A: Q/FTime frame: 0 minute to 5 days
- Part A: AUC0-tauTime frame: 0 minute to 5 days
- Part A: CmaxTime frame: 0 minute to 5 days
- Part A: KinTime frame: 0 minute to 35 days
- Part A: KoutTime frame: 0 minute to 35 days
- Part A: KdegTime frame: 0 minute to 35 days
- Part A: SlopeTime frame: 0 minute to 35 days
- The proportion of subjects whose platelet count is ≥50×10^9/L within 24 hours before surgery and has increased by ≥20×10^9/L from baseline, and who have not received platelet transfusion or other treatments to raise platelet levels before surgeryTime frame: 0 minute to 11 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital, affiliated with Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.